Drug Profile
Research programme: Parkinson's disease therapeutics - Exelixis
Alternative Names: Nurr1 receptor modulators - ExelixisLatest Information Update: 20 Jun 2006
Price :
$50
*
At a glance
- Originator Exelixis
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 20 Jun 2006 No development reported - Preclinical for Parkinson's disease in USA (unspecified route)
- 12 Nov 2004 X-Ceptor Therapeutics has been acquired by Exelixis
- 30 Sep 2004 Preclinical trials in Parkinson's disease in USA (unspecified route)